How Adequan® Canine works

Adequan® Canine (Polysulfated glycosaminoglycan or PSGAG) is a disease modifying osteoarthritis drug (DMOAD) recommended for the treatment of noninfectious degenerative and/or traumatic arthritis and associated lameness of canine synovial joints.

• Inhibits proteolytic enzymes
  that degrade cartilage and exacerbate
  inflammation in diseased joints.

• Improves joint function
  by stimulating synovial membrane activity,
  reducing synovial inflammation, and
  increasing synovial fluid hyaluronic
  acid content. ***

• Diminishes the catabolic processes
  that lead to loss of cartilage
  matrix components.

• Addresses the disease process,
  decreases articular pain and improves
  range of motion of arthritic joints.***

Recommended dose is 4.4 mg/kg (2 mg/lb)
by IM injection 2 times a week for a maximum
of 8 injections over a 4 week period.
Avoid IV administration.

 

*RoushJK, McLaughlin RM, Radlinsky MAG. Understanding the pathosphysiology of osteoarthritis. Vet Med 2002 Feb: 97 (2) : 108-12,116-17.
**Tranquilli WJ, Grimm KA, Lamont LA. Pain Management for the Small Animal Practitioner. Jackson (WY): Teton NewMedia;2000. Section 5, managing chronic pain in dogs and cats; 104-14.
***Burba D, et al, In Vivo Kinetic study on uptake and distribution of intrmuscular tritium-labeled Polysulfated Glycosaminoglycan in equine body fluid compartments and articular cartilage in an osteohealth defect model.
The Journal of Equine Vet Science; 13(12), 1993.